Friday, 4 September 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 16, 2026

Is Shell (LSE:SHEL) Still Attractive After A 43% One-Year Share Price Gain?

View original at finance.yahoo.com
“The latest twelve month free cash flow is about US$23.94b.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Shell scores 4 out of 6 on Simply Wall St's valuation checks, suggesting it screens as undervalued on most, but not all, metrics

    60% confidence
  • DCF analysis suggests Shell is undervalued by 54.0% with an estimated intrinsic value of US$72.77 per share compared to current price of £33.46

    60% confidence
  • Analyst forecasts and Simply Wall St extrapolations indicate free cash flow of US$27.30b in 2030

    60% confidence

Data points we hold from this source

Shell plc · stock return 1w-1.6 percent
Shell plc · stock return ytd21.3 percent
Shell plc · stock return 1y43.0 percent
Shell plc · stock return 1m-2.0 percent
Shell plc · free cash flow23.94 USD
Shell plc · free cash flow forecast27.30 USD
Shell plc · valuation score4 out_of_6
Shell plc · intrinsic value dcf72.77 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com
Is Shell (LSE:SHEL) Still Attractive After A 43% One-Year Share Price Gain? — Source | Via News | ViaNews EU